Wasserman Brad E, Carvajal-Hausdorf Daniel E, Ho Kenneth, Wong Wendy, Wu Natalie, Chu Victor C, Lai Edwin W, Weidler Jodi M, Bates Michael, Neumeister Veronique, Rimm David L
Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Division of Oncology Research and Development, Cepheid, Sunnyvale, CA, USA.
Lab Invest. 2017 Dec;97(12):1521-1526. doi: 10.1038/labinvest.2017.93. Epub 2017 Sep 11.
Historically, mRNA measurements have been tested on several commercially available platforms, but none have gained broad acceptance for assessment of HER2. An mRNA measurement, as a continuous value, has the potential for use in adjudication of the equivocal category. Here we use a real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) assay in a closed, single-use cartridge, automated system. Multiple cores (1 mm in diameter) were retrospectively collected from 80 formalin-fixed paraffin-embedded (FFPE) tissue blocks with invasive breast cancer seen by Yale Pathology Labs between 1998 and 2011. Tissue cores were processed with a FFPE lysis kit to create lysates that were tested with the automated RT-qPCR assay. Results for IHC and FISH were extracted from the pathology reports and quantitative immunofluorescence (QIF) for each case was measured as previously described. Quality control testing showed that the GX platform RT-qPCR shows no case to case cross contamination on material from routine histology practices. Concordance between RT-qPCR and IHC/FISH was 91.25% (sensitivity=0.87; specificity=0.94; PPV=0.89; NPV=0.92) using a pre-defined delta Ct cut-off (dCt≥-1) for HER2. Concordance (OPA) between RT-qPCR and QIF was 94% (sensitivity=0.90; specificity=0.96; PPV=0.93; NPV=0.94) using dCt≥-1 and a previously defined cut-point for positivity by QIF. In conclusion, the closed system RT-qPCR assay shows >90% concordance with the ASCO/CAP HER2 IHC/FISH scoring. Additionally, the RT-qPCR assay is highly concordant (94%) with the continuous variable HER2 QIF assay, and may better reflect the true continuum of HER2 receptor status in invasive breast cancer. These initial results suggest that fast, closed system molecular assays may have future value for the adjudication of the ASCO/CAP HER2 equivocal category or possibly routine usage in time constrained or low resource settings.
从历史上看,mRNA检测已在多个商用平台上进行过测试,但没有一个平台在HER2评估方面获得广泛认可。作为一个连续值的mRNA检测,有可能用于判定不确定类别。在此,我们在一个封闭的一次性试剂盒自动化系统中使用实时定量逆转录聚合酶链反应(RT-qPCR)检测法。从耶鲁病理实验室在1998年至2011年期间所见的80例浸润性乳腺癌福尔马林固定石蜡包埋(FFPE)组织块中回顾性收集多个核心(直径1毫米)。组织核心用FFPE裂解试剂盒处理以产生裂解物,然后用自动化RT-qPCR检测法进行检测。免疫组化(IHC)和荧光原位杂交(FISH)的结果从病理报告中提取,并且如前所述测量每个病例的定量免疫荧光(QIF)。质量控制测试表明,GX平台RT-qPCR在常规组织学操作的材料上未显示病例间交叉污染。使用针对HER2预先定义的ΔCt截止值(dCt≥ -1),RT-qPCR与IHC/FISH之间的一致性为91.25%(敏感性 = 0.87;特异性 = 0.94;阳性预测值 = 0.89;阴性预测值 = 0.92)。使用dCt≥ -1和先前定义的QIF阳性切点,RT-qPCR与QIF之间的一致性(OPA)为94%(敏感性 = 0.90;特异性 = 0.96;阳性预测值 = 0.93;阴性预测值 = 0.94)。总之,封闭系统RT-qPCR检测法与美国临床肿瘤学会/美国病理学家协会(ASCO/CAP)HER2 IHC/FISH评分的一致性>90%。此外,RT-qPCR检测法与连续变量HER2 QIF检测法高度一致(94%),并且可能更好地反映浸润性乳腺癌中HER2受体状态的真实连续性。这些初步结果表明,快速、封闭系统分子检测法可能在判定ASCO/CAP HER2不确定类别方面具有未来价值,或者可能在时间受限或资源有限的环境中常规使用。